Advanced arthritis, complete tendon tears, labral damage, disc herniations, and bone spurs generally show minimal response to peptide therapy
There is one open-label intravenous safety pilot in two healthy adults, who received single doses of 10 mg and 20 mg with no comparator, no blinding, and short-term observation limited to vital signs, self reported symptoms and labs across two days [4]
FOXO4-DRI: Senolytic Peptide Mechanism and the p53-FOXO4 Axis FOXO4-DRI is a D-retro-inverso peptide that selectively kills senescent cells by disrupting the protective FOXO4-p53 interaction
Each batch is tested for purity before release
The peptides are administered with a very fine needle, similar to what's used for insulin, just under the skin in the abdomen
Every intervention has trade-offs